TABLE 1.
Baseline demographic characteristics and previous malarial histories of subjects on tafenoquine and mefloquine for malaria prophylaxis
| Characteristic | Value for subjects who received: |
|
|---|---|---|
| Tafenoquine (n = 492) | Mefloquine (n = 162) | |
| No. (%) of subjects | ||
| Gender | ||
| Male | 478 (97.2) | 154 (95.1) |
| Female | 14 (2.8) | 8 (4.9) |
| Age (yr) | ||
| 18-25 | 286 (58.1) | 97 (59.9) |
| 26-35 | 178 (36.2) | 48 (29.6) |
| 36-45 | 27 (5.5) | 16 (9.9) |
| 46-55 | 1 (0.2) | 1 (0.6) |
| Race | ||
| White | 484 (98.4) | 160 (98.8) |
| Aboriginal/Torres Strait Islander | 4 (0.8) | 1 (0.6) |
| Other | 4 (0.8) | 1 (0.6) |
| Previous history of malaria | 15 (3.0) | 4 (2.5) |
| Having malaria attacks in 6 mo prior to deployment | 9 (1.8) | 1 (0.6) |
| Age | ||
| Mean (SD) | 25.4 (5.3) | 26.0 (6.5) |
| Range | 18-47 | 18-51 |
| Weight (kg) | ||
| Mean (SD) | 80.9 (11.9) | 81.3 (12.2) |
| Range | 50-135 | 53-135 |
| Height (cm) | ||
| Mean (SD) | 177.8 (7.0) | 177.1 (6.7) |
| Range | 155-198 | 157-192 |